← Back to Screener
Phibro Animal Health Corporation Class A (PAHC)
Price$53.88
Favorite Metrics
Price vs S&P 500 (26W)44.25%
Price vs S&P 500 (4W)-0.50%
Market Capitalization$2.24B
P/E Ratio (Annual)46.43x
Indicated Dividend Yield (Annual)0.87%
All Metrics
P/CF (Annual)27.97x
Book Value / Share (Quarterly)$8.21
P/TBV (Annual)4.15x
Indicated Dividend (Annual)$0.48
Revenue Growth (3Y)11.21%
Cash Flow / Share (Quarterly)$1.17
Payout Ratio (TTM)21.13%
Price vs S&P 500 (YTD)44.60%
Gross Margin (TTM)32.56%
Net Profit Margin (TTM)6.29%
EPS (TTM)$2.26
10-Day Avg Trading Volume0.29M
EPS Excl Extra (TTM)$2.26
Revenue Growth (5Y)10.12%
EPS (Annual)$1.19
Dividend / Share (Annual)$0.48
ROI (Annual)4.81%
Gross Margin (Annual)31.59%
Net Profit Margin (5Y Avg)3.81%
Cash / Share (Quarterly)$1.84
P/E Basic Excl Extra (TTM)24.34x
Revenue Growth QoQ (YoY)20.90%
EPS Growth (5Y)7.42%
P/E Normalized (Annual)46.43x
ROA (Last FY)3.55%
Revenue Growth TTM (YoY)32.39%
EBITD / Share (TTM)$5.38
ROE (5Y Avg)14.19%
Operating Margin (TTM)11.53%
Cash Flow / Share (Annual)$1.03
P/B Ratio6.74x
P/B Ratio (Quarterly)4.56x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.99x
Net Interest Coverage (TTM)2.60x
ROA (TTM)6.74%
EPS Growth QoQ (YoY)757.42%
EV / EBITDA (TTM)13.28x
EPS Incl Extra (Annual)$1.19
Current Ratio (Annual)2.76x
Quick Ratio (Quarterly)1.22x
3-Month Avg Trading Volume0.28M
52-Week Price Return207.15%
EV / Free Cash Flow (Annual)69.73x
P/E Incl Extra (TTM)24.34x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$7.39
P/S Ratio (Annual)1.73x
Asset Turnover (Annual)0.95x
52-Week High$60.08
Operating Margin (5Y Avg)7.69%
EPS Excl Extra (Annual)$1.19
CapEx CAGR (5Y)2.38%
Tangible BV CAGR (5Y)16.29%
26-Week Price Return48.23%
Quick Ratio (Annual)1.25x
13-Week Price Return38.11%
Total Debt / Equity (Annual)2.52x
Current Ratio (Quarterly)3.05x
Enterprise Value$2,916.85
Revenue / Share Growth (5Y)10.03%
Asset Turnover (TTM)1.07x
Book Value / Share Growth (5Y)8.69%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.50x
Pretax Margin (Annual)5.25%
Cash / Share (Annual)$1.90
3-Month Return Std Dev59.92%
Gross Margin (5Y Avg)31.15%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)8.98%
EBITDA Interim CAGR (5Y)17.71%
ROE (Last FY)16.89%
Net Interest Coverage (Annual)3.96x
EPS Basic Excl Extra (Annual)$1.19
P/FCF (TTM)43.27x
Receivables Turnover (TTM)7.18x
EV / Free Cash Flow (TTM)61.68x
Total Debt / Equity (Quarterly)2.20x
EPS Incl Extra (TTM)$2.26
Receivables Turnover (Annual)6.52x
ROI (TTM)8.95%
Dividend Growth Rate (5Y)0.02%
P/S Ratio (TTM)1.53x
Pretax Margin (5Y Avg)5.50%
Revenue / Share (Annual)$31.87
Tangible BV / Share (Annual)$6.15
Forward P/E18.20x
Free OCF CAGR (5Y)10.58%
Price vs S&P 500 (52W)177.32%
P/E Ratio (TTM)24.34x
EPS Growth TTM (YoY)373.82%
Year-to-Date Return47.24%
5-Day Price Return-6.90%
EPS Normalized (Annual)$1.19
ROA (5Y Avg)3.78%
Net Profit Margin (Annual)3.72%
Month-to-Date Return-0.54%
Cash Flow / Share (TTM)$1.36
EBITD / Share (Annual)$3.84
EPS Growth (3Y)-0.78%
Operating Margin (Annual)8.52%
LT Debt / Equity (Annual)2.46x
P/CF (TTM)24.08x
ROI (5Y Avg)5.03%
P/E Excl Extra (TTM)24.34x
LT Debt / Equity (Quarterly)2.14x
EPS Basic Excl Extra (TTM)$2.26
P/TBV (Quarterly)5.07x
Payout Ratio (Annual)40.30%
P/B Ratio (Annual)3.62x
Dividend / Share (TTM)$0.48
Inventory Turnover (TTM)2.09x
Pretax Margin (TTM)8.62%
Book Value / Share (Annual)$7.05
Price vs S&P 500 (13W)37.42%
Net Margin Growth (5Y)-2.40%
Dividend Yield (TTM)0.87%
Beta0.68x
P/FCF (Annual)53.58x
Revenue / Share (TTM)$35.75
ROE (TTM)30.81%
52-Week Low$16.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.44
2.44
2.44
2.44
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PAHCPhibro Animal Health Corporation Class A | 1.53x | 32.39% | 32.56% | 7.42% | $53.88 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Phibro Animal Health Corp provides diversified animal health and mineral nutrition products for food-producing animals including poultry, swine, beef cattle, dairy cattle, and aquaculture. The company manufactures and markets antibacterials, anticoccidials, vaccines, and specialty nutritional products through three segments: Animal Health (its primary revenue driver), Mineral Nutrition, and Performance Products. The company operates in the United States and international markets.